您的位置: 首页 > 农业专利 > 详情页

Pharmaceutical compositions for the treatment of inflammatory disorders
专利权人:
GALAPAGOS NV;ABBVIE INC.;ABBVIE DEUTSCHLAND GMBH & CO. KG
发明人:
申请号:
ARP150100350
公开号:
AR099306A1
申请日:
2015.02.06
申请国别(地区):
AR
年份:
2016
代理人:
摘要:
Pharmaceutical compositions. Useful in the prophylaxis and / or treatment of inflammatory conditions, autoimmune diseases, allergies, proliferative diseases, Transplant rejection, Diseases involving the degradation and / or rupture of the homeostasis of Cartilage, cartilage defects, and / or disease. Des associated with hypersecretion of ll6 interferons.Claim 1: a Pharmaceutical composition comprising: (i) 1 to 50% by weight of a hydrochloric acid salt of the compound of Formula 1 (1), (ii) 49.9 - 94% by weight of a Solid Inert diluent; and (iii) 0.1 to 5% by weight of a LUBRICANT. Claim 3: the pharmaceutical composition according to claim 1 or 2, where the solid Inert diluent is microcrystalline Cellulose.Claim 2: the pharmaceutical composition according to any one of claims 1 - 3, where the LUBRICANT is a non-ionic. Claim: The LUBRICANT 6 Pharmaceutical according to any one of claims 1 to 4, where oil is a Vegetable Oil, glycerol dibehenate Pegs, or 10000.Claim 12: a Pharmaceutical composition according to any one of claims 1 to 11, where the Salt of hydrochloric acid of compound 1 is an Adduct 1: 1: 1: 3: h u2082o Compound [HCl]. Claim 16: a Pharmaceutical composition according to any one of claims 1 to 15, which includes an additional Therapeutic Agent.Composiciones farmacéuticas. Útil en la profilaxis y/o tratamiento de afecciones inflamatorias, enfermedades autoinmunes, enfermedades proliferativas, alergia, rechazo al trasplante, enfermedades que implican la degradación y/o ruptura de la homeostasis del cartílago, malformaciones congénitas del cartílago, y/o enfermedades asociadas con la hipersecreción de lL6 interferones. Reivindicación 1: Una composición farmacéutica que comprende: (i) 1 - 50% por peso de una sal de acido clorhídrico del Compuesto 1 de fórmula (1), (ii) 49,9 - 94% por peso de un diluyente sólido inerte; y (iii) 0,1 - 5% por peso de un lubricante. Reivindicación 3: La composición farmacéutica de acuerdo con la reivindicación 1 ó 2, en dond
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充